New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Indivior Pharmaceuticals announced findings from two U.S.-based real-world evidence studies demonstrating that adherence to its monthly injectable buprenorphine treatment, SUBLOCADE, significantly lowers relapse risk to opioid use, reduces infection rates like bacteremia, and decreases healthcare utilization including inpatient, emergency, and outp…